Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with an unmet need for novel precision based therapies. While KRAS canonically drives tumor progression, MYC amplification has emerged as a critical downstream resistance mechanism. Efforts have been made to elucidate the role of MYC amplification in PDAC...
Audrey G. Sawyer, Lauryn E. Flannagan, Paulina N. Esguerra et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality and comprises molecular subtypes characterized by MYC amplification (14%) or MYC overexpression (40%), both of which drive tumor proliferation, metabolic reprogramming, and cellular plasticity. MYC dysregulation is associated w...
Paulina N. Esguerra, Michela Cadarso, Sasha Livingwell et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains a leading cause of cancer related mortality with a critical need for novel therapeutic strategies. Cyclin dependent kinase 9 (CDK9) is a transcriptional regulator of RNA polymerase II (Pol II) by phosphorylation of serine residues on the C terminal domain of the pos...
Michela Cadarso, Paulina N. Esguerra, Lauryn E. Flannagan et al.· Cancer Research· 0 citations
The rate of acquired resistance to Zoldonrasib was found to be rapid in PCO models and independent of EGF stimulation, and opposing signaling pathway activation in resistant PCOs to Zoldonrasib at 200nM dependent upon EGF stimulation was suggested.
Lauryn E. Flannagan, Michela Cadarso, Audrey G. Sawyer et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
